STOCK TITAN
  1. Home
  2. News
  3. MBOT

Microbot Medical Inc - MBOT STOCK NEWS

Welcome to our dedicated news page for Microbot Medical (Ticker: MBOT), a resource for investors and traders seeking the latest updates and insights on Microbot Medical.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Microbot Medical's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Microbot Medical's position in the market.

News
Microbot Medical Shares Status Following Recent Geopolitical Events
Rhea-AI Summary
Microbot Medical Inc. (MBOT) remains resilient amidst recent geopolitical events in Israel, with all regulatory, clinical, operational, and pre-commercial activities progressing as planned. The company is confident in achieving regulatory and commercial milestones on schedule, including FDA IDE submission, ISO 13485 certification audits, and partnerships for future capabilities of the LIBERTY® Endovascular Robotic Surgical System.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.98%
Tags
none
-
News
Microbot Medical Submits an IDE Application to Gain FDA Approval to Commence Its Pivotal Clinical Trial in the US
Rhea-AI Summary
Microbot Medical Inc. (MBOT) has filed an Investigational Device Exemption (IDE) application with the US Food and Drug Administration (FDA) for its LIBERTY® Endovascular Robotic Surgical System. The approval of the IDE application would allow the company to commence its pivotal human clinical trial in the United States. This marks an important milestone for the company in its journey to achieve FDA clearance for the surgical system.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.48%
Tags
clinical trial fda approval
-
News
Microbot Medical Announces Settlement and Release Agreement, Effectively Resolving all Associated Legal Matters
Rhea-AI Summary
Microbot Medical Inc. (MBOT) has signed a Settlement Agreement and Release with several entities, resolving all claims asserted against the Company in a lawsuit filed in 2020. The settlement amount, over half of which will be covered by Microbot's insurance carrier, will not impact the company's cash position or balance sheet. CEO Harel Gadot believes that resolving this matter while maintaining the company's cash position is in the best interest of shareholders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.71%
Tags
none
News
Microbot Medical Expands US Clinical Infrastructure in Support of the Upcoming IDE Submission to Commence its First in Human Clinical Study
Rhea-AI Summary
Microbot Medical Inc. (Nasdaq: MBOT) announces the addition of a US-based Clinical Research Associate (CRA) to support its anticipated IDE submission for its first in human clinical trial following positive results of its pivotal GLP pre-clinical study. The CRA will join the established clinical team in the USA, led by Dr. Juan Diaz-Cartelle, the Company’s Chief Medical Officer. This move aims to establish the right infrastructure for clinical trial execution.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.35%
Tags
clinical trial
-
News
Microbot Medical Announces Exercise of Outstanding Preferred Investment Options for $2.73 Million in Gross Proceeds Priced At-the-Market Under Nasdaq Rules
Rhea-AI Summary
Microbot Medical Inc. (Nasdaq: MBOT) announced the immediate exercise of certain outstanding preferred investment options to purchase up to 1,685,682 shares of common stock at a reduced exercise price of $1.62 per share. The offering is expected to close soon.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-20%
Tags
none
-
News
Microbot Medical Announced Positive Results of Its GLP Pivotal Pre-Clinical Study Where All Study Objectives Were Met
Rhea-AI Summary
Microbot Medical Inc. (Nasdaq: MBOT) has announced the successful completion of its GLP pivotal pre-clinical study for its LIBERTY® Endovascular Robotic Surgical System. The study, conducted using a porcine model, involved 96 robotic navigations and resulted in positive outcomes in the histopathology report. The Company plans to submit its IDE application to the FDA and commence its pivotal human clinical trial soon, marking an important milestone in its transition to a clinically stage company.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
55.3%
Tags
clinical trial
News
Microbot Medical and Corewell Health Forge Collaboration to Establish the LIBERTY® Endovascular Robotic Surgical System for Telerobotic
Rhea-AI Summary
Microbot Medical Inc. (Nasdaq: MBOT) collaborates with Corewell Health™ to evaluate LIBERTY® Robotic Surgical System for remote endovascular treatments. The agreement aims to enable telerobotics between remote centers, led by Dr. Ryan Madder, M.D., an interventional cardiology expert.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.25%
Tags
none
-
News
Microbot Medical Announces the Successful Completion of Its GLP Pivotal Pre-Clinical Study, a Critical Milestone for Its IDE submission to Commence Human Clinical Study
Rhea-AI Summary
Microbot Medical Inc. (Nasdaq: MBOT) successfully completed its GLP pivotal pre-clinical study for the LIBERTY Endovascular Robotic Surgical System. The study results will support the company's IDE submission to the FDA for commencing the human clinical study. Three leading interventional radiologists conducted the study, utilizing the robotic system for 96 navigations, leading to positive histopathology report outcomes. The CEO, Harel Gadot, expressed confidence in the company's transition to the clinical, regulatory, and pre-commercial phase.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.83%
Tags
clinical trial
-
News
Microbot Medical Appoints Seasoned Medical Expert Dr. Juan Diaz- Cartelle as its New Chief Medical Officer in Anticipation of Its Clinical, Regulatory and Commercial Activities
Rhea-AI Summary
Microbot Medical Inc. (MBOT) appoints Dr. Juan Diaz-Cartelle, former Senior Medical Director at Boston Scientific Corporation, as its new Chief Medical Officer. Dr. Diaz-Cartelle's appointment coincides with the Company's transition to focus on U.S.-based activities, including clinical trials and FDA regulatory processes for the LIBERTY Endovascular Robotic Surgical System.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.46%
Tags
management
News
Microbot Medical Successfully Completed Integral Part of the Verification and Validation Process
Rhea-AI Summary
Microbot Medical Inc. (Nasdaq: MBOT) successfully completed the Electromagnetic Compatibility (EMC) testing section of the Verification and Validation (V&V) process for its LIBERTY Robotic Surgical System. This achievement is a crucial step towards the company's regulatory submission and the FDA's approval for clinical trials. The V&V process ensures that the product aligns with specified requirements and serves its intended purpose, highlighting Microbot's commitment to quality and safety standards.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.47%
Tags
none
Stock MBOT logo
Microbot Medical Inc

Nasdaq:MBOT

MBOT Rankings

#5311 Ranked by Market Cap
#5156 Ranked by Stock Gains
N/A Ranked by Dividends

MBOT Stock Data

14.54M
14.15M
1.68%
12.21%
1.2%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Hingham

About MBOT

microbot medical was founded with the vision of pioneering micro invasive surgery, transforming one of the biggest trends in healthcare - minimally invasive surgery (estimated to be close to $20b by 2015); the company will provide transformational micro invasive technologies with the accuracy of robots and automated instruments to assist physicians in targeting the disease site with exquisite precision. microbot will solve one of the largest unmet needs in the medical field, where morbidity as a result of surgery is more frequently due to trauma involved in gaining access to the area to perform the intended procedure rather than from the procedure itself. through its unique platforms, microbot will reach multiple surgical spaces, capitalizing on the fact that minimally invasive techniques have been applied to most of the surgical specialties. microbot’s virob platform is an autonomous advancing micro robot (aamr), less then 1mm in diameter, which has the ability to advance (forward/bac